Tratamiento con fluoxetina para la ambliopía en adultos: resultados preliminares

Carlos Kotlik

doi:10.70313/2718.7446.v15.n04.190

Authors

Carlos Kotlik Área Oftalmología, Facultad Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina Departamento de Oftalmología Pediátrica, Hospital Notti, Mendoza, Argentina.

DOI:

https://doi.org/10.70313/2718.7446.v15.n04.190

Keywords:

amblyopia, fluoxetine, neuroplasticity

Abstract

Objective: To evaluate the efficacy and safety of the use of fluoxetine for the treatment of amblyopia in adults.

Methods: A retrospective, non-comparative, single-center, case series study of adult patients with amblyopia treated with fluoxetine in Mendoza, Argentina was performed. The study included patients over 18 years of age, with unilateral amblyopia due to anisometropia or strabismus with an inter-ocular relation > 0.23 LogMAR and who had previously undergone treatment with occlusion for at least 2 months without improvement in visual acuity. Efficacy was evaluated by measuring visual acuity in LogMAR and safety was assessed by looking for possible adverse effects related to fluoxetine, which were investigated both in the ophthalmologic consultation and also in clinical control.

Results: A total of 12 patients (5 women and 7 men) with a mean age of 27 ± 7.2 years (20-40) were included in the study. Initial visual acuity of the series was 0.6 ± 0.1 LogMAR (0.4-1.0) and improved to 0.2 ± 0.1 LogMAR (0-0.5), with a statistically significant difference (p<0.01), representing a mean visual improvement of 0.4 ± 0.07 LogMAR (0.3-0.6).

Conclusion: Treatment with fluoxetine 10 mg/day in addition to occlusion for 3 months has been effective in improving visual ability in adult patients with amblyopia, without adverse effects. Further studies are needed to confirm the present results.

References

Hashemi H, Pakzad R MSc, Yekta A et al. Global and regional estimates of prevalence of amblyopia: a systematic review and meta-analysis. Strabismus 2018; 26: 168-183.

Hu B, Liu Z, Zhao J et al. The global prevalence of amblyopia in children: a systematic review and meta-analysis. Front Pediatr 2022; 10: 819998.

Gopal SKS, Kelkar J, Kelkar A, Pandit A. Simplified updates on the pathophysiology and recent developments in the treatment of amblyopia: a review. Indian J Ophthalmol 2019; 67: 1392-1399.

Castaldi E, Lunghi C, Morrone MC. Neuroplasticity in adult human visual cortex. Neurosci Biobehav Rev 2020; 112: 542-552.

Papageorgiou E, Asproudis I, Maconachie G et al. The treatment of amblyopia: current practice and emerging trends. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1061-1078.

Hensch TK, Quinlan EM. Critical periods in amblyopia. Vis Neurosci 2018; 35: E014.

Gottlob I, Stangler-Zuschrott E. Effect of levodopa on contrast sensitivity and scotomas in human amblyopia. Invest Ophthalmol Vis Sci 1990; 31: 776-780.

Gottlob I, Charlier J, Reinecke RD. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992; 33: 2722-2728.

Maya Vetencourt JF, Sale A, Viegi A et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008; 320: 385-388.

Shoshany TN, Michalak SM, Chinn RN et al. Evaluating amblyopia treatment success using the American Academy of Ophthalmology IRIS50 measures. Ophthalmology 2020; 127: 836-838.

Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508.

Abdal MO, Bhombal F, Nankani GJ et al. Evaluation of the efficacy of a new dichoptic digital platform to treat the anisometropic and isometropic amblyopia. Brain Sci 2022; 12: 815.

Sharif MH, Talebnejad MR, Rastegar K et al. Oral fluoxetine in the management of amblyopic patients aged between 10 and 40 years old: a randomized clinical trial. Eye (Lond) 2019; 33: 1060-1067.

Edinoff AN, Akuly HA, Hanna TA et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 2021; 13: 387-401.

Leet MP, Bear MF, Gaier ED. Metaplasticity: a key to visual recovery from amblyopia in adulthood? Curr Opin Ophthalmol 2022; 33: 512-518.